Aeglea BioTherapeutics, Inc , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases.
infoAeglea BioTherapeutics is a micro cap stock with a total market cap of 55.55M.
infoThey trade on the NASDAQ and had their IPO 7 years and 4 months ago.
infoAeglea BioTherapeutics currently employs 14 people.
infoAs of Wednesday, Aug 23 2023, Aeglea BioTherapeutics’s share price is $0.549.
News Relating to Aeglea BioTherapeutics
PennyStocks
Best Penny Stocks To Watch? 4 Under $5 For Your List
Wednesday Jul 12 2023 at 15:34
Are you looking for the best penny stocks to watch right now? With all of the excitement in the stock market today, you’re not alone.
PennyStocks
Top Penny Stocks To Buy? 3 To Watch Before Next Week
Thursday Jul 06 2023 at 15:42
With the uptick of volatility in the stock market today, there’s no question as to why penny stocks are red hot. Whether the broader markets are risk-on or risk-off, the stock market is crashing or rallying, or if there’s a significant global catalyst, cheap stocks are usually a topic of discussion.
PennyStocks
Best Penny Stocks To Buy? 4 To Watch Before July 4th
Monday Jul 03 2023 at 11:04
The Fourth of July Holiday in 2023 will see the stock market closed for a full session. But that doesn’t mean fewer opportunities to make money in the stock market.
PennyStocks
10 Top Penny Stocks To Watch Right Now For Under $1
Thursday Jun 29 2023 at 13:20
Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.
PennyStocks
7 Penny Stocks To Watch Right Now For Under $1
Tuesday Jun 27 2023 at 15:37
Have you ever dreamt of uncovering a hidden gem in the stock market, something that could turn your modest investment into a jackpot? Welcome to the world of penny stocks.
Zacks Investment Research
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
Friday Jun 23 2023 at 11:54
Aeglea’s (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.
InvestorPlace
Why Is Aeglea BioTherapeutics (AGLE) Stock Up 392% Today?
Thursday Jun 22 2023 at 11:42
Aeglea BioTherapeutics (NASDAQ: AGLE ) stock is undergoing a massive rally on Thursday after it announced its acquisition of Spyre Therapeutics. Aeglea BioTherapeutics has completed its acquisition of the privately-held biotechnology company.
PennyStocks
Best Penny Stocks to Buy Under $1? 10 To Watch Now
Thursday Jun 22 2023 at 10:01
Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1.
Zacks Investment Research
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates
Thursday May 11 2023 at 09:56
Aeglea Biotherapeutics (AGLE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.37 per share a year ago.
PennyStocks
10 Top Penny Stocks To Watch Under $1
Tuesday Apr 25 2023 at 12:52
Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Seeking Alpha
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race
Monday Apr 24 2023 at 22:42
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race.
PennyStocks
Penny Stocks to Buy Now? 7 Under $1 To Watch This Week
Monday Apr 24 2023 at 10:52
Penny stocks to watch under $1 this week. The post Penny Stocks to Buy Now?
PennyStocks
3 Top Penny Stocks Under $1 To Watch Before Next Week
Friday Apr 21 2023 at 13:18
Penny stocks to buy for under $1 but are they worth the risk? The post 3 Top Penny Stocks Under $1 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research
Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails
Thursday Apr 13 2023 at 11:25
Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.
Zacks Investment Research
Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade
Wednesday Dec 14 2022 at 13:32
Aeglea (AGLE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
PennyStocks
Best Penny Stocks To Buy Now That CPI Is Out? 4 To Watch Before Next Week
Thursday Nov 10 2022 at 13:29
Hot penny stocks to watch after October’s CPI report. The post Best Penny Stocks To Buy Now That CPI Is Out?
Zacks Investment Research
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates
Thursday Nov 03 2022 at 09:47
Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PennyStocks
4 Penny Stocks To Buy According To Analysts Right Now
Tuesday Nov 01 2022 at 10:18
Penny stocks with bullish analyst ratings. Time to buy or avoid entirely?
PennyStocks
Why Are Penny Stocks Volatile? 3 Reasons and How to Profit
Saturday Oct 29 2022 at 11:00
This is why penny stocks are so volati The post Why Are Penny Stocks Volatile? 3 Reasons and How to Profit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
5 Top Penny Stocks To Watch With News Before Next Week
Friday Oct 28 2022 at 10:46
Penny stocks to watch this week with news. The post 5 Top Penny Stocks To Watch With News Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Benzinga
Paltalk And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
Friday Aug 26 2022 at 12:03
The Dow Jones tumbled by over 500 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Zacks Investment Research
Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down
Thursday Aug 25 2022 at 13:33
Aeglea (AGLE) announces a corporate restructuring plan to prioritize the development of AGLE-177 for patients living with homocystinuria. The company’s current CEO resigns.
Zacks Investment Research
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
Monday Aug 22 2022 at 13:33
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
PennyStocks
Buying Penny Stocks Right Now? 3 to Watch This Week
Monday Aug 22 2022 at 06:00
Here’s what you need to know about trading penny stocks on August 22nd The post Buying Penny Stocks Right Now? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
4 Penny Stocks To Watch With Bullish Buys From Options Traders
Friday Aug 19 2022 at 12:17
Penny stocks with unusual options activity today. The post 4 Penny Stocks To Watch With Bullish Buys From Options Traders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research
Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug
Friday Jun 03 2022 at 12:03
Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.
Zacks Investment Research
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates
Thursday May 05 2022 at 09:03
Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA
Wednesday Apr 13 2022 at 14:18
Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA.
Zacks Investment Research
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates
Tuesday Mar 08 2022 at 09:47
Aeglea (AGLE) delivered earnings and revenue surprises of 3.12% and 18.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
PRNewsWire
Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022
Wednesday Jan 05 2022 at 07:01
AUSTIN, Texas , Jan. 5, 2022 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows: Conference: 40th Annual J.P. Morgan Health Care Conference, January 10-13, 2022 Live Presentation Date/Time: Wednesday, January 12 at 10:30 a.m.
Aeglea BioTherapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Aeglea BioTherapeutics’s Altman Z-score is -6.55 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Aeglea BioTherapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Aeglea BioTherapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Aeglea BioTherapeutics’s Income Quality of 0.25 is lower than its Industry Group of 0.69 (-63.8% lower)
Aeglea BioTherapeutics’s Income Quality of 0.25 is lower than its Major Industry Group of 0.71 (-64.8% lower)
Aeglea BioTherapeutics’s Income Quality of 0.25 is lower than its Sector of 0.75 (-66.7% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Aeglea BioTherapeutics’s Current Ratio of 1.03 is lower than its Industry Group of 4.76 (-78.4% lower)
Aeglea BioTherapeutics’s Current Ratio of 1.03 is lower than its Major Industry Group of 4.32 (-76.2% lower)
Aeglea BioTherapeutics’s Current Ratio of 1.03 is lower than its Sector of 2.6 (-60.4% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.2 & -1.27)
Cannot compare a negative PE Ratio (-0.2 & -1.1)
Cannot compare a negative PE Ratio (-0.2 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compare a negative PB Ratio (-5.53 & 1.34)
Cannot compare a negative PB Ratio (-5.53 & 1.4)
Cannot compare a negative PB Ratio (-5.53 & 1.62)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Aeglea BioTherapeutics’s ROE of 27.13 is greater than its Industry Group of -0.44 (6265.9% greater)
Aeglea BioTherapeutics’s ROE of 27.13 is greater than its Major Industry Group of -0.38 (7239.5% greater)
Aeglea BioTherapeutics’s ROE of 27.13 is greater than its Sector of -0.03 (90533.3% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Aeglea BioTherapeutics’s ROCE of -19.12 is lower than its Industry Group of -0.42 (-4452.4% lower)
Aeglea BioTherapeutics’s ROCE of -19.12 is lower than its Major Industry Group of -0.37 (-5067.6% lower)
Aeglea BioTherapeutics’s ROCE of -19.12 is lower than its Sector of -0.04 (-47700.0% lower)
Derived from SEC.GOV filing dataopen_in_new